Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Minimum 10-Year Outcomes of Matrix-Induced Autologous Chondrocyte Implantation in the Knee: A Systematic Review
Wang, Allen S. , Nagelli, Christopher V. , Saris, Daniël B.F. , Krych, Aaron J. , Krych, Aaron J , Wang, Allen , Lamba, Abhinav , Hevesi, Mario

Mayo Clinic

The American Journal of Sports Medicine | February 5, 2024 | Volume: 52 | Issue: 9 | Pages: 2407-2414

10.1177/03635465231205309 | PMID 38312085 Get It

Background: Matrix-induced autologous chondrocyte implantation (MACI) is an established cell-based therapy for the treatment of chondral defects of the knee. As long-term outcomes are now being reported in the literature, it is important to systematically review available evidence to better inform clinical practice. Purpose: To report (1) subjective patient-reported outcomes (PROs) and (2) the rate of graft failure, reoperation, and progression to total knee arthroplasty (TKA) after undergoing MACI of the knee at a minimum 10-year follow-up. Study Design: Systematic review; Level of evidence, 4. Methods: A comprehensive search of Ovid MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily; Ovid Embase; Ovid Cochrane Central Register of Controlled Trials; Ovid Cochrane Database of Systematic Reviews; and Scopus from 2008 to September 15, 2022, was conducted in the English language. Study eligibility criteria included (1) full-text articles in the English language, (2) patients undergoing a MACI within the knee, (3) clinical outcomes reported, and (4) a minimum 10-year follow-up. Results: In total, 168 patients (99 male, 69 female; mean age, 37 years [range, 15-63 years]; mean body mass index, 26.2 [range, 18.6-39.4]) representing 188 treated chondral defects at a minimum 10-year follow-up after MACI were included in this review. Significant and durable long-term improvements were observed across multiple PRO measures. Follow-up magnetic resonance imaging (MRI), when performed, also demonstrated satisfactory defect fill and an intact graft in the majority of patients. The all-cause reoperation rate was 9.0%, with an overall 7.4% rate of progression to TKA at 10 to 17 years of follow-up. Conclusion: At a minimum 10-year follow-up, patients undergoing MACI for knee chondral defects demonstrated significant and durable improvements in PROs, satisfactory defect fill on MRI-based assessment, and low rates of reoperation and TKA. These data support the use of MACI as a long-term treatment of focal cartilage defects of the knee.
Outcomes of Shoulder Instability Surgery in Competitive Wrestlers: Outcomes, Reoperations, and Return to Play at 5 Years’ Mean Follow-up
Lamba, Abhinav , Boos, Alexander M. , Wang, Allen S. , Okoroha, Kelechi R. , Krych, Aaron J. , Camp, Christopher L. , Marigi, Erick M. , Lamba, Abhinav , Boos, Alexander , Wang, Allen , Krych, Aaron J , Camp, Christopher L. , Barlow, Jonathan D.

Mayo Clinic

The American Journal of Sports Medicine | February 2, 2024 | Volume: 52 | Issue: 3 | Pages: 586-593

10.1177/03635465231218262 | PMID 38305257 Get It

Background: Wrestling is a physically demanding sport with young athletes prone to traumatic shoulder instability and a paucity of data evaluating the results of shoulder instability surgery (SIS). Purpose: To assess reoperation rates, patient-reported outcomes, and return to wrestling (RTW) after SIS in a cohort of competitive wrestlers. Study Design: Case series; Level of evidence, 3. Methods: All competitive wrestlers with a history of shoulder instability and subsequent surgery at a single institution between 1996 and 2020 were identified. All directions of shoulder instability (anterior shoulder instability [ASI], posterior shoulder instability [PSI], and traumatic multidirectional shoulder instability [TMDI]) were analyzed. Exclusions included revision SIS and <2 years of follow-up. Athletes were contacted for determination of complications, RTW, and Western Ontario Shoulder Instability Index scores. Results: Ultimately, 104 wrestlers were included with a mean age at initial instability of 16.9 years (range, 12.0-22.7 years), mean age at surgery of 18.9 years (range, 14.0-29.0 years), and a mean follow-up of 5.2 years (range, 2.0-22.0 years). A total of 58 (55.8%) wrestlers were evaluated after a single shoulder instability event, while 46 (44.2%) sustained multiple events before evaluation. ASI was the most common direction (n = 79; 76.0%), followed by PSI (n = 14; 13.5%) and TMDI (n = 11; 10.6%). Surgical treatment was most commonly an arthroscopic soft tissue stabilization (n = 88; 84.6%), with open soft tissue repair (n = 13; 12.5%) and open bony augmentation (n = 3; 2.9%) performed less frequently. RTW occurred in 57.3% of wrestlers at a mean of 9.8 months. Recurrent instability was the most common complication, occurring in 18 (17.3%) wrestlers. Revision SIS was performed in 15 (14.4%) wrestlers. Across the entire cohort, survivorship rates free from recurrent instability and revision surgery were 90.4% and 92.5% at 2 years, 71.9% and 70.7% at 5 years, and 71.9% and 66.5% at 10 years, respectively. Preoperative recurrent instability was an independent risk factor for postoperative recurrent instability (hazard ratio, 3.8; 95% CI, 1.33-11.03; P = .012). Conclusion: Competitive wrestlers with multiple dislocations before initial clinical evaluation were 3.8 times more likely to experience postoperative recurrent instability. Patients should be counseled that despite SIS, only 57.3% returned to wrestling after surgery.
Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA
Ailawadhi, Sikander , Ravelo, Arliene , Ng, Carmen D. , Shah, Bonny, Lamarre, Neil, Wang, Rongrong , Eakle, Katherine, Biondo, Juliana ML, Ailawadhi, Sikander , Biondo, Juliana M.L.

Mayo Clinic

Journal of Comparative Effectiveness Research | January 31, 2024 | Volume: 13 | Issue: 2 | Pages: No page available

10.57264/cer-2023-0119 | PMID 38294335 Get It

Aim: Improved management of chronic lymphocytic leukemia (CLL) has resulted in a growing population of CLL survivors; these patients have a higher risk of developing second primary malignancies (SPMs) versus the general population. This retrospective cohort study aims to assess the timing, frequency, incidence and types of SPMs in treated and untreated patients with CLL in the USA, using the Surveillance, Epidemiology, and End Results (SEER) Medicare database, which links a nationally representative cancer registry with Medicare claims data. Patients & methods: Patients aged ≥66 years with newly diagnosed CLL between 1 January 2010 and 31 December 2016, who were enrolled in Parts A and B of Medicare for ≥12 months pre-diagnosis of CLL were selected from the database. Patients were assessed for ≥36 months until the end of continuous enrollment in Medicare Parts A, B and D, a switch to a health maintenance organization, death, or end of the study period (December 2019). Results: Of 3053 patients included in the analyses, 620 (20.3%) were treated and 2433 (79.7%) were untreated within 36 months of diagnosis. Overall, 638 (20.9%) patients developed a SPM, 26.8% of patients in the treated cohort and 19.4% of patients in the untreated cohort. The most common SPMs for both cohorts were squamous cell carcinoma and acute myeloid leukemia. Among the 166 treated patients who developed a SPM, a greater proportion developed their first SPM after treatment initiation versus those who developed their first SPM prior to treatment initiation (p < 0.001). A significantly lower percentage of patients who received targeted therapy developed a SPM (p < 0.05) versus patients treated with anti-CD20 + chemotherapy. Conclusion: Findings indicate that treatment type and timing can affect SPM development in patients with CLL. Combined with previous findings, this can help inform best practices in monitoring for SPM in patients with CLL.
Dynamic Prognosis Prediction for Patients on DAPT After Drug‐Eluting Stent Implantation: Model Development and Validation
Li, Fang , Rasmy, Laila , Xiang, Yang , Feng, Jingna , Abdelhameed, Ahmed , Hu, Xinyue , Sun, Zenan , Aguilar, David , Dhoble, Abhijeet , Du, Jingcheng , Wang, Qing , Zhang, Xinyuan , Xie, Ziqian , Nian, Yi , He, Jianping , Zhou, Yujia , Li, Jianfu , Prosperi, Mattia , Bian, Jiang , Zhi, Degui , Niu, Shuteng , Dang, Yifang , Zhang, Xinyuan , Xie, Ziqian , Nian, Yi , He, JianPing , Zhou, Yujia , Li, Jianfu , Prosperi, Mattia , Bian, Jiang , Zhi, Degui , Tao, Cui , Sun, Zenan , Li, Fang , Niu, Shuteng , Dang, Yifang , Tao, Cui

Mayo Clinic

Journal of the American Heart Association | January 31, 2024 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/jaha.123.029900 | PMID 38293921 Get It

Background The rapid evolution of artificial intelligence (AI) in conjunction with recent updates in dual antiplatelet therapy (DAPT) management guidelines emphasizes the necessity for innovative models to predict ischemic or bleeding events after drug‐eluting stent implantation. Leveraging AI for dynamic prediction has the potential to revolutionize risk stratification and provide personalized decision support for DAPT management. Methods and Results We developed and validated a new AI‐based pipeline using retrospective data of drug‐eluting stent‐treated patients, sourced from the Cerner Health Facts data set (n=98 236) and Optum's de‐identified Clinformatics Data Mart Database (n=9978). The 36 months following drug‐eluting stent implantation were designated as our primary forecasting interval, further segmented into 6 sequential prediction windows. We evaluated 5 distinct AI algorithms for their precision in predicting ischemic and bleeding risks. Model discriminative accuracy was assessed using the area under the receiver operating characteristic curve, among other metrics. The weighted light gradient boosting machine stood out as the preeminent model, thus earning its place as our AI‐DAPT model. The AI‐DAPT demonstrated peak accuracy in the 30 to 36 months window, charting an area under the receiver operating characteristic curve of 90% [95% CI, 88%–92%] for ischemia and 84% [95% CI, 82%–87%] for bleeding predictions. Conclusions Our AI‐DAPT excels in formulating iterative, refined dynamic predictions by assimilating ongoing updates from patients' clinical profiles, holding value as a novel smart clinical tool to facilitate optimal DAPT duration management with high accuracy and adaptability.
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
Yacoub, Abdulraheem , Borate, Uma , Rampal, Raajit K. , Ali, Haris , Gerds, Aaron T. , Kremyanskaya, Marina , Winton, Elliott F., Goel, Swati , Schiller, Gary J. , McCloskey, James, Palmer, Jeanne , Holmes, Houston, Hager, Steven, Assad, Albert , Erickson‐Viitanen, Susan, Zhou, Feng , Gerds, Aaron T , Goel, Swati , Oh, Stephen T , Palmer, Jeanne M , Daver, Naval , Wang, Eunice S. , Hobbs, Gabriela , O'Connell, Casey Lee , Oh, Stephen T. , Daver, Naval

Mayo Clinic

Blood Advances | January 30, 2024 | Volume: 8 | Issue: 6 | Pages: 1515-1528

10.1182/bloodadvances.2023011620 | PMID 38290135 Get It

Abstract Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, and safety of add-on PI3Kδ inhibitor parsaclisib for patients with primary or secondary myelofibrosis with suboptimal response to ruxolitinib. Eligible patients remained on a stable ruxolitinib dose and received add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, and once weekly thereafter (daily-to-weekly dosing; n = 32); or parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing; n = 42). Proportion of patients achieving a ≥10% decrease in spleen volume at 12 weeks was 28% for daily-to-weekly dosing and 59.5% for all-daily dosing. Proportions of patients achieving ≥50% decrease at week 12 in Myelofibrosis Symptom Assessment Form and Myeloproliferative Neoplasms Symptom Assessment Form symptom scores were 14% and 18% for daily-to-weekly dosing, and 28% and 32% for all-daily dosing, respectively. Most common nonhematologic treatment-emergent adverse events were nausea (23%), diarrhea (22%), abdominal pain and fatigue (each 19%), and cough and dyspnea (each 18%). New-onset grade 3 and 4 thrombocytopenia were observed in 19% of patients, each dosed daily-to-weekly, and in 26% and 7% of patients dosed all-daily, respectively, managed with dose interruptions. Hemoglobin levels remained steady. The addition of parsaclisib to stable-dose ruxolitinib can reduce splenomegaly and improve symptoms, with manageable toxicity in patients with myelofibrosis with suboptimal response to ruxolitinib. This trial was registered at www.clinicaltrials.gov as #NCT02718300.
Lung Cancer Screening Results Among Population of Different Genders, Ages, Smokers and Non-smokers: A Study Based on Real World Data
Bao, Ting , Li, Zhenzhen , Ji, Guiyi , Tang, Huairong , Yang, Hanwei , Huang, Yan , Wang, Youjuan , Yang, Ping , Li, Weimin

Mayo Clinic

No container title available | January 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.170666202.25160823/v1 Get It

Background Analysis of the real-world data of low-dose spiral CT screening of healthy physical examination population in Southwest China from 2006 to 2017, discussed the standard of low-dose spiral CT screening for high-risk population of lung cancer in China. Methods Incorporate all team subjects who have undergone LDCT screenings at the Health Management Center of West China Hospital of Sichuan University between 2006 and 2017, and analyze the cumulative incidence and age-standardized (Segi population) incidence of lung cancer in the whole population; finally, analysis the age-specific, smoking and non-smokers’ lung cancer incidence. Results A total of 15,996 people who met the enrollment conditions and participated in the LDCT lung cancer screening were included. The average screening interval was 1.12±0.26 years, and the average follow-up time was 5.43±0.82 years; The cumulative number of lung cancer cases with negative baseline screening was 56 cases, and the cumulative incidence rate of lung cancer was 122.1/100,000 (the world standard rate is 60.6/100,000), of which males were 100.0/100,000 (the world standard rate is 45.3/100,000) and women were 156.6 /100,000 (the world standard rate is 94.7/100,000); the cumulative incidence of lung cancer in the smoking group is higher than that in the non-smoking group for both males and females, but the cumulative incidence of lung cancer in the non-smokers of the female population (146.3/100,000) is higher than that of the male population (86.5/10 Million). Conclusion In the real world study of lung cancer screening in Chinese population, we should consider setting different standards for high-risk groups of lung cancer by gender or smoking and non-smokers.
Staphylococcus aureus proteases trigger eosinophil-mediated skin inflammation
Kline, Sabrina N. , Orlando, Nicholas , Lee, Alex J. , Wu, Meng-Chen , Zhang, Jing , Youn, Christine , Feller, Laine , Pontaza, Cristina , Dikeman, Dustin , Limjunyawong, Nathachit , Williams, Kaitlin L. , Wang, Yu , Jacobsen, Elizabeth A. , Dong, Xinzhong , Archer, Nathan K. , Orlando, Nicholas A , Wu, Meng-Jen , Feller, Laine E , Jacobsen, Elizabeth A , Garza, Luis A , Archer, Nathan K , Nolan, Sabrina J. , Čiháková, Daniela , Durum, Scott Kenneth

Mayo Clinic

Proceedings of the National Academy of Sciences | January 30, 2024 | Volume: 121 | Issue: 6 | Pages: No page available

10.1073/pnas.2309243121 | PMID 38289950 Get It

Staphylococcus aureus skin colonization and eosinophil infiltration are associated with many inflammatory skin disorders, including atopic dermatitis, bullous pemphigoid, Netherton’s syndrome, and prurigo nodularis. However, whether there is a relationship between S. aureus and eosinophils and how this interaction influences skin inflammation is largely undefined. We show in a preclinical mouse model that S. aureus epicutaneous exposure induced eosinophil-recruiting chemokines and eosinophil infiltration into the skin. Remarkably, we found that eosinophils had a comparable contribution to the skin inflammation as T cells, in a manner dependent on eosinophil-derived IL-17A and IL-17F production. Importantly, IL-36R signaling induced CCL7-mediated eosinophil recruitment to the inflamed skin. Last, S. aureus proteases induced IL-36α expression in keratinocytes, which promoted infiltration of IL-17-producing eosinophils. Collectively, we uncovered a mechanism for S. aureus proteases to trigger eosinophil-mediated skin inflammation, which has implications in the pathogenesis of inflammatory skin diseases.
Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Long, Jessica B., Rabil, Maximilian , Sprenkle, Preston C. , Kim, Isaac Yi, Saperstein, Lawrence, Suzman, Daniel L. , Lerro, Catherine, Xu, Jianjin , Karnes, R. Jeffrey , Gross, Cary P. , Leapman, Michael , Westvold, Sarah J. , Fallah, Jaleh , Kluetz, Paul Gustav , Kunst, Natalia , Wang, Shi‐Yi , Ma, Xiaomei

Mayo Clinic

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: 34-34

10.1200/jco.2024.42.4_suppl.34 Get It

34 Background: Prostate specific membrane antigen positron emission tomography (PSMA-PET) imaging improves prostate cancer visualization and has been proposed as a tool to guide treatment decisions. As PSMA-PET imaging agents were not approved in the United States (US) until December 2020, little is known about national patterns of PET imaging utilization. Methods: We conducted a dynamic cohort study to evaluate use of PET imaging among insurance beneficiaries aged 40-89 years with a diagnosis of prostate cancer using deidentified administrative claims from Blue Cross Blue Shield Axis. We calculated the proportions of patients undergoing PET imaging in semiannual periods from January 1, 2016, through December 31, 2022, examining tracers specific to prostate cancer, including PSMA-targeted agents as well as fluciclovine, sodium fluoride, and choline tracers. Cochran-Armitage tests were used to evaluate trends in the proportion of individuals receiving PET imaging over time. We also assessed the association between regional [hospital referral region (HRR)] level contextual sociodemographic and healthcare characteristics and regional use of PSMA-PET imaging in 2022 using chi-square tests. Results: There were 410,505 beneficiaries with prostate cancer identified in the study period. The semiannual proportion of patients undergoing PET imaging increased from 4.5 [(95% confidence interval (CI) 4.1-5.0] per 1,000 in the first half of 2016 to 41.7 (95% CI 40.6-42.9) per 1,000 in the second half of 2022, p<0.001. Increases in PET imaging were driven by uptake of PSMA-PET imaging, which increased from 0.7 (95% CI 0.6-0.9) per 1000 in the second half of 2021 to 37.5 (95% CI 36.4-38.6) per 1,000 in the second half of 2022, p<0.001. Following approvals of PSMA-PET agents, other forms of PET imaging rapidly decreased – from 18.2 (95% CI 17.4-18.9) per 1000 in the second half of 2021 to 4.6 (95% CI 4.3-5.0) per 1,000 in the same period of 2022, p<0.001. Compared to HRRs in quartile 1 (Q1), HRRs in Q4 of PSMA-PET use in 2022 had higher levels of education (25.0% with college education or higher in Q1 versus 29.4% in Q4, p=0.005) and median household income ($50,200 in Q1 versus $60,900 in Q4, p<0.001). Conclusions: In this study from a large commercial US health insurer, PSMA-PET was rapidly incorporated into clinical practice and is now the dominant prostate cancer radiotracer. However, the initial uptake of PSMA-PET may be accompanied by disparity, as our data suggests less use in areas with lower income and education measures.
Real-world Trends, Rural-urban Differences, and Socioeconomic Disparities in Utilization of Narrow versus Broad Next-generation Sequencing Panels
Zhao, Yiqing , Dimou, Anastasios , Fogarty, Zachary C. , Liu, Hongfang , Wong, William B. , Wang, Chen , Liu, Hongfang , Jiang, Jun , Liu, Hongfang , Wong, William B , Wang, Chen , Fogarty, Zachary C , Dimou, Anastasios , Jiang, Jun

Mayo Clinic

Cancer Research Communications | January 26, 2024 | Volume: 4 | Issue: 2 | Pages: 303-311

10.1158/2767-9764.crc-23-0190 | PMID 38276870 Get It

Abstract Advances in genetic technology have led to the increasing use of genomic panels in precision oncology practice, with panels ranging from a couple to hundreds of genes. However, the clinical utilization and utility of oncology genomic panels, especially among vulnerable populations, is unclear. We examined the association of panel size with socioeconomic status and clinical trial matching. We retrospectively identified 9,886 eligible adult subjects in the Mayo Clinic Health System who underwent genomic testing between January 1, 2016 and June 30, 2020. Patient data were retrieved from structured and unstructured data sources of institutional collections, including cancer registries, clinical data warehouses, and clinical notes. Socioeconomic surrogates were approximated using the Area Deprivation Index (ADI) corresponding to primary residence addresses. Logistic regression was performed to analyze relationships between ADI or rural/urban status and (i) use of genomic test by panel size; (ii) clinical trial matching status. Compared with patients from the most affluent areas, patients had a lower odds of receiving a panel test (vs. a single-gene test) if from areas of higher socioeconomic deprivation [OR (95% confidence interval (CI): 0.71 (0.61–0.83), P &lt; 0.01] or a rural area [OR (95% CI): 0.85 (0.76–0.96), P &lt; 0.01]. Patients in areas of higher socioeconomic deprivation were less likely to be matched to clinical trials if receiving medium panel tests [(OR) (95% CI): 0.69 (0.49–0.97), P = 0.03]; however, there was no difference among patients receiving large panel tests (P &gt; 0.05) and rural patients were almost 2x greater odds of being matched if receiving a large panel test [(OR) (95% CI): 1.76 (1.21–2.55), P &lt; 0.01]. Significance: We identified socioeconomic and rurality disparities in the use of genomic tests and trial matching by panel size, which may have implications for equal access to targeted therapies. The lack of association between large panel tests and clinical trial matching by socioeconomic status, suggests a potential health equity impact, while removing barriers in access to large panels for rural patients may improve access to trials. However, further research is needed.
Targeting Src SH3 domain–mediated glycolysis of HSC suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis
Wang, Yuanguo , Wang, Xianghu , Bai, Bing , Shaha, Aurpita , He, Xipu , He, Yingzi, Ye, Zhenqing, Shah, Vijay H. , Kang, Ningling , Bai, Bing , He, Yingzi

Mayo Clinic

Hepatology | January 25, 2024 | Volume: 80 | Issue: 3 | Pages: 578-594

10.1097/hep.0000000000000763 | PMID 38271673 Get It

Background and Aims: Transforming growth factor-beta 1 (TGFβ1) induces HSC activation into metastasis-promoting cancer-associated fibroblasts (CAFs), but how the process is fueled remains incompletely understood. We studied metabolic reprogramming induced by TGFβ1 in HSCs. Approaches and Results: Activation of cultured primary human HSCs was assessed by the expression of myofibroblast markers. Glucose transporter 1 (Glut1) of murine HSC was disrupted by Cre recombinase/LoxP sequence derived from bacteriophage P1 recombination (Cre/LoxP). Plasma membrane (PM) Glut1 and glycolysis were studied by biotinylation assay and the Angilent Seahorse XFe96 Analyzer. S.c. HSC/tumor co-implantation and portal vein injection of MC38 colorectal cancer cells into HSC-specific Glut1 knockout mice were performed to determine in vivo relevance. Transcriptome was obtained by RNA sequencing of HSCs and spatialomics with MC38 liver metastases. TGFβ1-induced CAF activation of HSCs was accompanied by elevation of PM Glut1, glucose uptake, and glycolysis. Targeting Glut1 or Src by short hairpin RNA, pharmacologic inhibition, or a Src SH3 domain deletion mutant abrogated TGFβ1-stimulated PM accumulation of Glut1, glycolysis, and CAF activation. Mechanistically, binding of the Src SH3 domain to SH3 domain–binding protein 5 led to a Src/SH3 domain–binding protein 5/Rab11/Glut1 complex that activated Rab11-dependent Glut1 PM transport under TGFβ1 stimulation. Deleting the Src SH3 domain or targeting Glut1 of HSCs by short hairpin RNA or Cre recombinase/LoxP sequence derived from bacteriophage P1 recombination suppressed CAF activation in mice and MC38 colorectal liver metastasis. Multi-omics revealed that Glut1 deficiency in HSCs/CAFs suppressed HSC expression of tumor-promoting factors and altered MC38 transcriptome, contributing to reduced MC38 liver metastases. Conclusion: The Src SH3 domain–facilitated metabolic reprogramming induced by TGFβ1 represents a target to inhibit CAF activation and the pro-metastatic liver microenvironment.